Head-to-head · computed 2026-08-11
bmiMD vs Henry Meds
bmiMD: bmiMD is a compounded GLP-1 telehealth platform notable for flat per-dose pricing — the rate stays the same whether you're at 2.5 mg or 15 mg — and one of the widest plan-tier menus in the market. Its $99/mo semaglutide and $139/mo tirzepatide on the twelve-month plan are the lowest annualized figures in the dataset for both molecules. Henry Meds: Henry's all-inclusive semaglutide runs $297/month ($247 on 6-month and $197 on 12-month prepaid bundles) and tirzepatide $349/month; a separately marketed 'as low as $149' microdose floor is a different program.
Tirzepatide
| bmiMD | Henry Meds | |
|---|---|---|
| All-in maintenance | $179/mo | $179/mo |
| Best plan rate | $139/mo | $179/mo |
| 12-month total | $1,668 | $2,148 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-14 |
The arithmetic
On monthly cost the two are tied at $179; the decision comes down to structure — bmiMD's (flat — same price at every dose, across all plan lengths) against Henry Meds's (flat — $179/mo tirzepatide and $179/mo semaglutide at every dose, per reported sources).
bmiMD's tirzepatide ladder runs $179 a month billed monthly, $159 a month on a three-month plan, $149 a month on a six-month plan, and $139 a month on a twelve-month plan. Henry Meds's runs $179 a month billed monthly. On the twelve-month basis bmiMD's $1,668 beats Henry Meds's $2,148 by $480 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Semaglutide
| bmiMD | Henry Meds | |
|---|---|---|
| All-in maintenance | $129/mo | $179/mo |
| Best plan rate | $99/mo | $197/mo |
| 12-month total | $1,188 | $2,364 |
| Status | Reported · 2026-07-14 | Provider-stated · 2026-08-05 |
The arithmetic
On the figures our desk holds, bmiMD's $129 a month undercuts Henry Meds's $297 by $168 a month at the 2.4 mg/wk maintenance basis — $2,016 across a year. bmiMD's figure is reported (captured 2026-07-14) and Henry Meds's is provider-stated (captured 2026-08-05); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
bmiMD's semaglutide ladder runs $129 a month billed monthly, $119 a month on a three-month plan, $109 a month on a six-month plan, and $99 a month on a twelve-month plan. Henry Meds's runs $297 a month billed monthly, $247 a month on a six-month plan, and $197 a month on a twelve-month plan. On the twelve-month basis bmiMD's $1,188 beats Henry Meds's $2,364 by $1,176 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Where the structures genuinely differ
On exit terms, bmiMD's structure avoids prepaid lock-in while Henry Meds's better rates ride prepaid terms — cheaper per month, costlier to leave early; read the refund language before choosing the discount.
Structure, side by side
bmiMD
- MembershipNone
- Dose policyFlat — same price at every dose, across all plan lengths
- CommitmentMonthly, 3-month, 6-month, or 12-month plans; price varies by term, not by dose
- CancellationPer provider terms; confirm cancellation policy at enrollment
- PharmacyNamed 503A pharmacy partner (specific pharmacy not publicly identified on pricin
Henry Meds
- MembershipNone
- Dose policyFlat — $179/mo tirzepatide and $179/mo semaglutide at every dose, per reported sources
- CommitmentMonth-to-month; 6/12-month bundles prepaid
- CancellationCancel before renewal; bundle refunds limited
- PharmacyPartner pharmacies
What our desk is watching on each
bmiMD: bmiMD's 12-month semaglutide plan at $99/mo is the lowest annualized sema figure in our dataset, beating NexLife's $119/mo and Oak's $133 m2m. Month-to-month sema at $129 also beats Oak's $133, making bmiMD the new m2m sema leader. Tirzepatide 12-month at $139 ties NexLife. Figures are reported status from RangeYourself's July 2026 first-party captures; our independent checkout is pending.
Henry Meds: Two independent 2026 captures (RangeYourself Jul 2026, RxPepsDirect May 2026) consistently show $179/mo flat for tirzepatide, replacing our Aug-5 $349 provider-stated figure. Henry's pharmacy partner is not publicly named. Semaglutide plan tiers ($179–$297) remain from our prior captures pending full reconciliation with the updated tirz figure.
Questions people ask
Is bmiMD or Henry Meds cheaper in 2026?
The tirzepatide and semaglutide verdict blocks above give the computed answer at the maintenance basis, with the verification status of each figure; the short version is that whichever program's all-in monthly number is lower on this page is cheaper on the evidence we hold today, and both rows carry capture dates so you can judge freshness.
What does bmiMD vs Henry Meds miss that checkout will show?
Taxes, state availability, current promotions, and any dose surcharge introduced after our capture date. Screenshot the order summary before paying — that capture, not any comparison page, is your contract.
Why do you compare at the maintenance dose instead of the starting dose?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year; comparing starts against maintenances is the single most common way GLP-1 comparisons mislead.
What do bmiMD and Henry Meds cost over a full year of tirzepatide?
On the plans our database holds, a year of tirzepatide runs $1,668 at bmiMD and $2,148 at Henry Meds — computed from each program's best published twelve-month route, with promotional figures labeled in the sections above and every number carrying its capture date.
Both records live in the normalized database; re-run the math yourself from the downloads. Full record pages: bmiMD · Henry Meds. Official sites: bmiMD ↗ · Henry Meds ↗. Nothing here is medical advice.